127 related articles for article (PubMed ID: 37019185)
1. Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells.
He M; Liao Q; Liu D; Dai X; Shan M; Yang M; Zhang Y; Zhai L; Chen L; Xiang L; He M; Li S; Chen A; Sun L; Lian J
Biochem Pharmacol; 2023 May; 211():115538. PubMed ID: 37019185
[TBL] [Abstract][Full Text] [Related]
2. Dichloroacetate enhances the anti-tumor effect of sorafenib via modulating the ROS-JNK-Mcl-1 pathway in liver cancer cells.
Sun L; Jiang Y; Yan X; Dai X; Huang C; Chen L; Li T; Zhang Y; Xiao H; Yang M; Xiang L; Zhang Y; Chen S; Li S; Chen A; He F; Lian J
Exp Cell Res; 2021 Sep; 406(1):112755. PubMed ID: 34332981
[TBL] [Abstract][Full Text] [Related]
3. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
Tai WT; Shiau CW; Chen HL; Liu CY; Lin CS; Cheng AL; Chen PJ; Chen KF
Cell Death Dis; 2013 Feb; 4(2):e485. PubMed ID: 23392173
[TBL] [Abstract][Full Text] [Related]
4. Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
Siddharth S; Kuppusamy P; Wu Q; Nagalingam A; Saxena NK; Sharma D
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897659
[TBL] [Abstract][Full Text] [Related]
5. AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
Gao M; Kong Q; Hua H; Yin Y; Wang J; Luo T; Jiang Y
Oncotarget; 2016 Mar; 7(13):16349-61. PubMed ID: 26918349
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
Chen CH; Chen MC; Wang JC; Tsai AC; Chen CS; Liou JP; Pan SL; Teng CM
Clin Cancer Res; 2014 Mar; 20(5):1274-1287. PubMed ID: 24520095
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Biochem; 2013 Aug; 114(8):1819-31. PubMed ID: 23463670
[TBL] [Abstract][Full Text] [Related]
8. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
10. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Wei G; Wang M; Hyslop T; Wang Z; Carr BI
Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.
Ding Q; Huo L; Yang JY; Xia W; Wei Y; Liao Y; Chang CJ; Yang Y; Lai CC; Lee DF; Yen CJ; Chen YJ; Hsu JM; Kuo HP; Lin CY; Tsai FJ; Li LY; Tsai CH; Hung MC
Cancer Res; 2008 Aug; 68(15):6109-17. PubMed ID: 18676833
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
Xu J; Huang F; Yao Z; Jia C; Xiong Z; Liang H; Lin N; Deng M
Cell Commun Signal; 2019 Jul; 17(1):85. PubMed ID: 31349793
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Sinicrope FA
Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft.
Yu HJ; Shin JA; Jung JY; Nam JS; Hong IS; Cho NP; Cho SD
Head Neck; 2015 Sep; 37(9):1326-35. PubMed ID: 25043125
[TBL] [Abstract][Full Text] [Related]
16. Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
Wang HL; Ma X; Guan XY; Song C; Li GB; Yu YM; Yang LL
Pharmacol Res; 2022 Mar; 177():106050. PubMed ID: 34973468
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
Fecteau JF; Bharati IS; O'Hayre M; Handel TM; Kipps TJ; Messmer D
Mol Med; 2012 Feb; 18(1):19-28. PubMed ID: 21979753
[TBL] [Abstract][Full Text] [Related]
18. Dihydroergotamine Tartrate Induces Lung Cancer Cell Death through Apoptosis and Mitophagy.
Chang SH; Lee AY; Yu KN; Park J; Kim KP; Cho MH
Chemotherapy; 2016; 61(6):304-12. PubMed ID: 27100100
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
20. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
Silberstein S
Expert Opin Pharmacother; 2012 Sep; 13(13):1961-8. PubMed ID: 22860628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
